PP13 and Doppler Study to Predict Preeclampsia

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Preeclampsia
Interventions
DRUG

Progesterone

40 units daily admission

DRUG

Low molecular weight Heparin

40-80 mg/day

DRUG

No Drug

no treatment

Trial Locations (1)

Unknown

Soroka Medical Center, Ben Gurion University, Beersheba

Sponsors
All Listed Sponsors
collaborator

Diagnostic Technologies Ltd.

INDUSTRY

collaborator

Perkin Elmer Inc.

INDUSTRY

collaborator

Medical University of Graz

OTHER

lead

Ben-Gurion University of the Negev

OTHER

NCT00928213 - PP13 and Doppler Study to Predict Preeclampsia | Biotech Hunter | Biotech Hunter